Latent Labs
Making biology programmable with generative AI
Latent Labs uses generative AI to design novel proteins for drug discovery. Founded by Dr. Simon Kohl, who co-developed AlphaFold 2 at Google DeepMind and co-led its protein design team, the company launched in February 2025 with $50M in funding. The team includes alumni from DeepMind, Google, Oxford, Stability AI, and Exscientia.
Foundation Models, Generative Chemistry, Antibody Design, Platform
Funding
$50M
Total raised
$40M
Led by Radical Ventures, Sofinnova Partners
Radical Ventures · Sofinnova Partners · 8VC · Kindred Capital · Pillar VC
Technology
Latent-X platform for generative protein design. Proprietary AI models trained on biological data combined with wet lab facilities for experimental validation. AWS collaboration to scale generative AI for life sciences.
Leadership
Simon Kohl
CEO & Founder
Former DeepMind senior research scientist; co-developed AlphaFold 2; co-led DeepMind protein design team
Similar companies
Absci Corporation
AI-powered de novo antibody design and creation
preclinical · 2011Boltz PBC
Open-source biomolecular AI for drug discovery
platform · 2026Cradle
Generative AI protein engineering platform
platform · 2021Generate:Biomedicines
Generative AI for de novo protein therapeutic design
preclinical · 2020Get updates on Latent Labs
We'll notify you when we publish updates about Latent Labs.